GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Enterprise Value

BioPlus Acquisition (BioPlus Acquisition) Enterprise Value

: $214.32 Mil (As of Today)
View and export this data going back to 2022. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioPlus Acquisition's Enterprise Value is $214.32 Mil. BioPlus Acquisition's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.16 Mil. Therefore, BioPlus Acquisition's EV-to-EBIT ratio for today is -99.13.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, BioPlus Acquisition's Enterprise Value is $214.32 Mil. BioPlus Acquisition's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.16 Mil. Therefore, BioPlus Acquisition's EV-to-EBITDA ratio for today is -99.13.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, BioPlus Acquisition's Enterprise Value is $214.32 Mil. BioPlus Acquisition's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil. Therefore, BioPlus Acquisition's EV-to-Revenue ratio for today is .


BioPlus Acquisition Enterprise Value Historical Data

The historical data trend for BioPlus Acquisition's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition Annual Data
Trend Dec21 Dec22
Enterprise Value
- 304.41

BioPlus Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Enterprise Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 296.05 299.45 304.41 310.96 211.51

Competitive Comparison

For the Shell Companies subindustry, BioPlus Acquisition's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPlus Acquisition Enterprise Value Distribution

For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Enterprise Value distribution charts can be found below:

* The bar in red indicates where BioPlus Acquisition's Enterprise Value falls into.



BioPlus Acquisition Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

BioPlus Acquisition's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

BioPlus Acquisition's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioPlus Acquisition  (NAS:BIOS) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

BioPlus Acquisition's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=214.319/-2.162
=-99.13

BioPlus Acquisition's current Enterprise Value is $214.32 Mil.
BioPlus Acquisition's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

BioPlus Acquisition's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=214.319/-2.162
=-99.13

BioPlus Acquisition's current Enterprise Value is $214.32 Mil.
BioPlus Acquisition's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

BioPlus Acquisition's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=214.319/0
=

BioPlus Acquisition's current Enterprise Value is $214.32 Mil.
BioPlus Acquisition's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioPlus Acquisition Enterprise Value Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPlus Acquisition (BioPlus Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000